Thursday, 24 September, 2026
Enveda Raises $311M to Advance AI-Discovered, Nature-Based Medicines Into Clinical Trials
By TechShots Studio
AI biotech startup Enveda has raised $311 million in Series E funding at a $2 billion valuation. The company uses AI to identify drug candidates from molecules found in plants and microbes. The funding will help advance three medicines through clinical development and bring additional candidates into trials for inflammatory and metabolic conditions. Enveda has raised more than $845 million since its 2019 founding.
Read full story at TECHCRUNCH